Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (48,481)	$ (43,252)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,006	984
Accretion of premium/discount on marketable securities	(1,954)	(1,586)
Non-cash lease expense	364	139
Amortization of debt issuance costs	17
Stock-based compensation expense	24,377	13,605
Change in fair value of contingent consideration	4,068	2,038
Other non-cash reconciling items	16	(2)
Change in operating assets and liabilities:
Accounts receivable	(24,624)
Inventory	(2,095)
Prepaid expenses, other current assets and other assets	(339)	380
Accounts payable	(2,603)	567
Accrued compensation	1,491	(986)
Accrued clinical trial site costs	37	(1,530)
Operating lease liabilities	(74)	(107)
Other liabilities	3,434	(429)
Net cash used in operating activities	(45,360)	(30,179)
Cash flows from investing activities:
Purchases of property and equipment	(14)	(19)
Purchases of marketable securities	(104,764)	(261,146)
Maturities of marketable securities	119,800	25,000
Net cash provided by (used in) investing activities	15,022	(236,165)
Cash flows from financing activities:
Payment of debt issuance costs	(62)
Payment of deferred financing costs	(178)
Proceeds from the sale of common stock, net of issuance costs		148,955
Proceeds from exercise of common stock warrants	5,187
Proceeds from exercise of common stock and pre-funded stock warrants		3,543
Proceeds received prior to and for the issuance of common stock and pre-funded warrants		637
Proceeds from exercise of stock options	13,993	552
Tax withholding payments for net share-settled equity awards	(33)
Net cash provided by financing activities	18,907	153,687
Net decrease in cash and cash equivalents	(11,431)	(112,657)
Cash and cash equivalents, beginning of period	87,928	169,681
Cash and cash equivalents, end of period	76,497	$ 57,024
Supplemental disclosure of non-cash operating and financing information
Cash paid for interest	$ 2,060